Targeted Gene Silencing in Malignant Hematolymphoid Cells Using GapmeR
- 1 September 2020
- book chapter
- Published by Springer Nature
- Vol. 2176, 209-219
Abstract
Delivery of conventional antisense oligonucleotides or small interfering RNA (siRNA) molecules into hematolymphoid cells for targeted gene silencing has been proven to be difficult. Here, we describe a simple protocol to knockdown specific gene(s) in malignant hematolymphoid cells using “GapmeR.” This protocol could be applicable to a wide range of cell-types and thus solves an important problem for researchers working with cell lines or primary cells derived from patients with hematolymphoid malignancies.Keywords
This publication has 22 references indexed in Scilit:
- Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM StudyClinical Colorectal Cancer, 2018
- STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trialJournal for ImmunoTherapy of Cancer, 2018
- Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trialThe Lancet Oncology, 2017
- Germline mutations predisposing to diffuse large B-cell lymphomaBlood Cancer Journal, 2017
- Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumorsCancer Chemotherapy and Pharmacology, 2013
- Mipomersen Sodium: First Global ApprovalDrugs, 2013
- The genetic landscape of mutations in Burkitt lymphomaNature Genetics, 2012
- Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trialThe Lancet, 2010
- Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular diseaseNature Reviews Drug Discovery, 2006
- A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with aidsAmerican Journal of Ophthalmology, 2002